Biochemical characterization of multiple myeloma patients across ISS stages – a data base workup from a tertiary care hospital in India

Noorjahan Mohammed, Sai Baba SS Kompella, Yadagiri Bhodramoni, Sadashivudu Gundeti, Bhushan Raju Sree

Abstract


Background: Multiple myeloma (MM) is slowly becoming a huge medical burden, challenging the health-care systems of Asian countries. Because of the unavailability of widespread access to various modalities of investigations, and paucity of well compiled data on common presenting features and various laboratory parameters in various stages of MM in India, the diagnosis is usually delayed till complications begin to occur. This study is an attempt to fill this gap and to establish database for future reference.

Methods: The study was conducted in a tertiary health care centre over a span of 3 years and 94 patients diagnosed as MM with complete workup including beta2 microglobulin (β2M), bone marrow plasma cell percentage, serum protein electrophoresis, serum and urine Immunofixation and serum Free Light Chains (FLC) were included. The various laboratory parameters were statistically analyzed across ISS stages I, II and III.

 Results: We found a male to female ratio of 1.47:1. The mean age of patients was 55.5±11.78 yrs. Backache was the most frequent presentation (30%) of the patients followed by generalized weakness (22%). The percentage of plasma cells, hemoglobin, urea, creatinine, uric acid, calcium and β2M showed significant difference across the stages. 38.3% of the patients were in stage III, 29.8% in stage II and 31.9% in stage I. IgGκ type constituted 70%, other fraction being IgGλ (10%), IgMκ (10%), IgAκ (5%) and IgAλ (5%). M band was not seen in 11% of patients.

Conclusion(s): The presentation of MM is nonspecific and patient can come with varied presentations at onset. We have biochemically characterized the three stages of MM and this will form a basis for further larger studies on these lines and to develop stage-based algorithms for early and better diagnosis and prognosis of MM.


Full Text:

PDF (FULL TEXT)

References


Fousad C, Gangadharan K V, Abdulla MC, Naryan R, Mohammed Ali M J. Clinical profile of multiple myeloma in South India. Indian J Med Paediatr Oncol, 2018; 39, 62-6.

Diwan AG, Gandhi SA, Krishna K, Shinde VP. Clinical profile of the spectrum of multiple myeloma in a teaching hospital. Med J DY Patil Univ, 2014; 7, 185-8.

AJ Madu, S Ocheni, TA Nwagha, OG Ibegbulam, US Anike.: Multiple myeloma in Nigeria: An insight to the clinical, laboratory features, and outcomes. Nigerian Journal of Clinical Practice, 2014; Mar-Apr .Vol 17, Issue 2, page- 212-17.

Kyle and Rajkumar, Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia, 2009; 23: 3–9.

Greipp PR, San Miguel J, Durie BG, et al: International staging system for multiple myeloma. J Clin Oncol, 2005; 23, 3412-20.

MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2018.

Kyle RA, Bayrd ED: Benign monoclonal gammopathy: a potentially malignant condition? Am I Med, 1966; 40, 426.

Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 1975; Sep; 36 (3), 842-54.

NCRP, 2001: National cancer registry programme. Consolidated report of population based cancer registries 1990-1996. ICMR New Delhi.

Wadhwa J et al. Multiple myeloma: A retrospective analysis of 534 patients. Dissertation topic. All India Institute of Medical Sciences (AIIMS), 1999; New Delhi, India.

Advani SH, Soman CS, Talwalkar GV, Lyer YS, Bhatia HM. Multiple-myeloma: review of 231 cases. Indian J Cancer, 1978; Jun, 15 (2), 55-61.

Tripathy S. The Role of Serum Protein Electrophoresis in the Detection of Multiple Myeloma. Journal of Clinical and Diagnostic Research, 2012;. November, Vol 6 (9): 1458-61.

Sridhar S, Dutta TK, Basu D. Clinical profile of multiple myeloma and effect of thalidomide based treatment on its outcome. J Indian Med Assoc, 2011; 109,880-2, 887-8.

Kaur P, Shah BS, Baja P. Multiple myeloma: a clinical and pathological profile. Gulf J Oncolog, 2014; 1, 14-20.

Gupta P, Kochupillai V et al. A 12 tears study of multiple myeloma at AIIMS, Ind J Med & Ped Oncol, 1995; Vol 16, 108-14.

Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc, 2003; 78, 21-33.

Attal M, Lauwers-Cances V, Hulin C, Facon T, Caillot D, Escoffre M, et al. Autologous transplantation for multiple myeloma in the era of new drugs: A phase III study of the Intergroupe Francophone du Myelome (IFM/DFCI 2009 Trial). Blood, 2015; 126, 391.

Subramanian R, Basu D, Dutta TK. Prognostic significance of bone marrow histology in multiple myeloma. Indian J Cancer, 2009; 46, 40-5.

Jacob LA, Suresh Babu M C, Lakshmaiah K C, Babu K G, Lokanatha D etal. Multiple myeloma: Experience of an institute in limited resource setting. Indian J Cancer, 2017; 54, 340-2.

Wang L, Wang KF, Chang BY, Chen XQ, Xia ZJ. Once-weekly subcutaneous administration of bortezomib in patients with multiple myeloma. Asian Pac J Cancer Prev, 2015; 16, 2093-8.

Durie BGM, Stock-Novack D, Salmon SE, et al. Prognostic value of pretreatment serum beta2 microglobulin in myeloma: A Southwest Oncology Group study. Blood, 1990; 75, 823-30.

Bataille R, Durie BGM, Grenier J. Serum beta 2 microglobulin and survival duration in multiple myeloma: A simple reliable marker for staging. Br J Haematol, 1983; 55, 439-47.

Ramasamy I.Hypocalcemia in multiple myeloma secondary to unrecognised Vitamin D deficiency: A case report. Bone, 2011; 48: S27-8.

Dimopoulos, M. A., Kastritis, E., Roussou, M., Gkotzamanidou, M., Migkou, et al. Elevated Serum Lactate Dehydrogenase (LDH) Should Be Included Among the Variables Which Define High Risk Multiple myeloma. Blood, 2010; 116(21), 2969.

Palumbo, A., H. Avet-Loiseau, S. Oliva, H. M. Lokhorst, H. Goldschmidt, L.et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J ClinOncol, 2015; 33, (26), 2863-9.

Cowan AJ, Allen C, Barac A, et al.. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol, 2018; 4 (9), 1221-7.

Kumar L.. Multiple Myeloma – The Indian Perspectives: Current situation. Comy, 2nd world congress, 2016.




DOI (PDF (FULL TEXT)): http://dx.doi.org/10.31557/APJCC.2019.4.3.77

Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Asia Pacific Journal of Cancer Care


 

  

PORTICO

 

Asia Pacific Organization for Cancer Prevention 

West Asia Organization for Cancer Prevention